BioMarin Pharmaceutical | BMRN - Debt


BioMarin Pharmaceutical reported $1.44B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 725.8M 1.82M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.02B 1.73B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026